Non Invasive Comprehensive Antigen Influenza PCR Kit High Sensitivity

Rapid Test Kit Antigen With Influenza A/B Rapid Test Kit 20 Tests High Sensitivity Comprehensive Rapid Test Kit

Intended Use
The rapid test kit is intended for qualitative detection and differentiation of nucleocapsid protein antigens from SARS-CoV-2, influenza type A and influenza type B in the same time directly from nasal/nasopharyngeal (NS/NP) swab, oropharyngeal (OP) swab and saliva specimens from patients with signs and symptoms of respiratory viral infection. The test kit is for professional use only.
Specification

Main Components

• Test cassettes
• Sample extraction buffers
• Sample tubes
• Swabs
• Tube Stand
• Package Insert

Use Step

• Take out the test cassette from the sealed pouch, place it on a clean and level surface with the sample port well up.

• Apply 2 full drops of the treated sample (60μl-70μl) vertically into each of the two sample wells of the test cassette.

• Observe the test results immediately within 15~20 minutes, the result is invalid over 20 minutes.

Interpretation Of Result

• POSITIVE: The presence of T (T on nCoV /A or B on Flu) and C lines within the reaction window indicate a positive result on SARS-CoV-2 or Flu A and/or B infection or co-infection.

• NEGATIVE: One colored line appears in the control region(C). No apparent colored line appears in the test region (T on nCoV /A or B on Flu). The negative result does not indicate the absence of analytes in the sample, it only indicates the level of tested analytes in the sample is less than the minimum detection limit

• INVALID: No colored lines appear, or control line fails to appear, indicating that the operator error or reagent failure. Verify the test procedure and repeat the test with a new testing device.

Feature

• Non-invasive
• Simple to use
• Convenient, no devices required
• Rapid, get result in 15 minutes
• Stable, with high accuracy
• Inexpensive, cost-efficiency

Priciple

• The SARS-CoV-2 Antigen & Influenza A/B Rapid Test Kit employs a lateral flow chromatographic technology to detect the presence of the nucleocapsid protein antigen directly from influenza A, influenza B, and SARS-CoV-2.
• After the patient sample is collected and treated with the antigen extraction buffer, the viral nucleoproteins antigen will be exposed. Add the extracted specimen into the test cassette, the specimen will migrate forward along with the test strips through capillary effect. If Influenza A, Influenza B, SARS-CoV or SARS-CoV-2 viral antigen is present, they will be captured and detected on the T or A/B line, respectively on each test strips within 15 minutes from the addition of the samples, resulting in purplish red band on the test region, indicating a positive result. If the nucleocapsid protein antigen is not present or present at very low levels in the sample, there is no red line appears in “T” or "A/B" positions. The “Control Line” (C) is used for procedural control.
• Control line should always appear if the test procedure is performed properly and the test reagents of control line are working.

FAQ

• About MOQ?

We have the limit order which is 10000, we would like to cooperate with you, don't worry about MOQ, just send us of your what items you want order.

• What is your lead time?

Stock 3-7 days in general. Or please contact us by email for specific lead time base on your order quantities.

• Accept OEM or ODM order?

Yes, we accept both OEM and ODM for customers.

• What are your terms of delivery?

We can accept EXW, FOB, CIF, etc. You can choose one which is the most convenient for you.

Labnovation Technologies, Inc. is an original manufacturer established in Shenzhen, China since 2001. We are dedicated in developing and manufacturing IVD instruments and reagents including HbA1c analyzer and reagents, rapid test reader & reagents, hematology reagents, clinical chemistry reagents, electrolyte reagents, wash solution and urine test reagents.

Labnovation products are developed in house, tested extensively in clinics and passed strict quality controls. All of our products are CE marked and approved by SFDA. In the past 15 years, our products have been exported to 110 different countries and used in 8000 hospitals worldwide. We provide both ready-to-use final products and bulk OEM reagents, including ready-to-use reagents, concentrated, and powder.

With an investment of 10% of our annual sales into R&D, we release new products every years. We win more and more domestic and international cooperation by company reputation and products quality while we actively take part in fairs like MEDICA,AACC, ARBA HEALTH and so on through which we are well-known by the companies in this field.